ClearPoint Neuro (NASDAQ:CLPT) Announces Earnings Results

Key Points

• ClearPoint Neuro beat earnings expectations: The company reported a quarterly loss of $0.24 per share, better than the consensus loss estimate of $0.32. Revenue totaled $12.07 million, slightly below analysts’ $12.30 million forecast.
• Shares rose 8.7% to $10.53 following the results, though the stock remains well below its 52-week high of $26.85 and the 50- and 200-day moving averages near $12.79 and $13.07, respectively.
• Analyst sentiment remains mixed, with two Buy ratings and one Sell rating producing a consensus Hold rating and a $25.67 price target. ClearPoint Neuro continues to report significant losses, including an 81.76% negative net margin and a 188.09% negative return on equity.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) released its earnings results on Wednesday. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.08, FiscalAI reports. The business had revenue of $12.07 million during the quarter, compared to analysts' expectations of $12.30 million. ClearPoint Neuro had a negative net margin of 81.76% and a negative return on equity of 188.09%.

ClearPoint Neuro Stock Up 8.7%

Shares of NASDAQ CLPT traded up $0.84 during midday trading on Wednesday, hitting $10.53. 863,763 shares of the stock traded hands, compared to its average volume of 714,001. ClearPoint Neuro has a one year low of $8.27 and a one year high of $26.85. The company has a market cap of $321.21 million, a PE ratio of -8.92 and a beta of 1.29. The business has a 50 day moving average price of $12.79 and a two-hundred day moving average price of $13.07. The company has a debt-to-equity ratio of 4.66, a quick ratio of 3.89 and a current ratio of 4.74.

Analyst Ratings Changes

Several research firms have issued reports on CLPT. Wall Street Zen lowered ClearPoint Neuro from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 8th. Stifel Nicolaus set a $22.00 target price on shares of ClearPoint Neuro in a research report on Tuesday, August 4th. Weiss Ratings restated a "sell (d-)" rating on shares of ClearPoint Neuro in a research note on Thursday, October 15th. Finally, Lake Street Capital set a $25.00 price target on ClearPoint Neuro in a report on Tuesday, August 4th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, ClearPoint Neuro has a consensus rating of "Hold" and a consensus price target of $25.67.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company that develops and commercializes platforms for minimally invasive procedures involving the brain. Its technology is designed to help physicians plan, navigate and deliver treatments with real-time magnetic resonance imaging (MRI) guidance, supporting more precise access to targeted areas of the brain.

The company's principal product is the ClearPoint Neuro Navigation System, which uses specialized software, instruments and accessories to guide neurosurgical procedures inside an MRI scanner.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.